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Background: E74-like factor 5 (ELF5) is an epithelial-specific member of the E26 transforming sequence (ETS)
transcription factor family and a critical regulator of cell fate in the placenta, pulmonary bronchi, and milk-producing
alveoli of the mammary gland. ELF5 also plays key roles in malignancy, particularly in basal-like and endocrine-resistant
forms of breast cancer. Almost all genes undergo alternative transcription or splicing, which increases the diversity of
protein structure and function. Although ELF5 has multiple isoforms, this has not been considered in previous studies
of ELF5 function.
Methods: RNA-sequencing data for 6757 samples from The Cancer Genome Atlas were analyzed to characterize ELF5
isoform expression in multiple normal tissues and cancers. Extensive in vitro analysis of ELF5 isoforms, including a
116-gene quantitative polymerase chain reaction panel, was performed in breast cancer cell lines.
Results: ELF5 isoform expression was found to be tissue-specific due to alternative promoter use but altered in
multiple cancer types. The normal breast expressed one main isoform, while in breast cancer there were subtype-
specific alterations in expression. Expression of other ETS factors was also significantly altered in breast cancer, with the
basal-like subtype demonstrating a distinct ETS expression profile. In vitro inducible expression of the full-length isoforms
1 and 2, as well as isoform 3 (lacking the Pointed domain) had similar phenotypic and transcriptional effects.
Conclusions: Alternative promoter use, conferring differential regulatory responses, is the main mechanism governing
ELF5 action rather than differential transcriptional activity of the isoforms. This understanding of expression and function
at the isoform level is a vital first step in realizing the potential of transcription factors such as ELF5 as prognostic markers
or therapeutic targets in cancer.
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Transcription factors are the integrators of multiple sig-
naling pathways, converting internal and external stimuli
into changes in gene expression. Through this role, the
evolutionarily conserved E26 transforming sequence
(ETS) transcription factor family controls fundamental
cellular processes such as proliferation, differentiation,
and apoptosis [1]. The 28 members of the human ETS
family are characterized by an ETS DNA-binding domain
that recognizes a core GGAA/T motif. Additional specifi-
city of ETS domain binding is conferred by the amino* Correspondence: c.piggin@garvan.org.au
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(http://creativecommons.org/publicdomain/zeacids surrounding the key residues, as well as by post-
translational modifications and interactions with other
proteins [2, 3]. Given the vital cellular processes regulated
by ETS transcription factors, it is not surprising that they
have also been identified as significant contributors to
tumorigenesis [4].
E74-like factor 5 (ELF5) is an epithelial-specific member
of the ETS transcription factor family [5, 6]. In addition to
the ETS domain, the full-length ELF5 protein contains an
N-terminal Pointed (PNT) domain (83 amino acids) that
is similar to the evolutionarily conserved sterile alpha
motif (SAM) domain. In humans, the SMART database
[7] identifies 96 SAM/PNT domain-containing proteins,
11 of which are ETS family members. SAM domains have
diverse functions, including protein–protein interactions,is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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molecule interactions [8–11]. The ELF5 PNT domain has
been shown to have strong transactivation activity [12];
however, the mechanisms underlying this activity (for
example, protein–protein interactions or posttranslational
modifications) are unknown.
A critical function of ELF5 is the regulation of cell fate,
beginning with specification of the trophectoderm in the
blastocyst [13]. Correct spatial and temporal ELF5 ex-
pression is also important for normal development of the
embryonic lung [14]. In the mammary gland, prolactin-
and progesterone-driven ELF5 expression during preg-
nancy directs the development of the luminal progenitor
cells into estrogen receptor-α (ER)- and progesterone re-
ceptor (PR)-negative milk-producing cells [15]. In normal
human tissues, ELF5 is reported to be expressed in the
kidney, prostate, lung, mammary gland, salivary gland,
placenta, and stomach [5, 6, 16].
More recently, there has been increasing interest in
the role of ELF5 in cancer. ETS factors are frequently
deregulated in cancer through diverse mechanisms, includ-
ing gene fusions, alterations in localization and/or activity,
amplifications, increased expression, and (less commonly
described) decreased expression [4]. ELF5 was originally
described as a tumor suppressor [5]; however, the role of
this protein in cancer is complex and context-dependent.
In prostate cancer, for example, ELF5 has been shown
to inhibit transforming growth factor (TGF)-β-driven
epithelial–mesenchymal transition by blocking phos-
phorylation of the TGF-β effector protein SMAD3 [17].
Conversely, ELF5 mRNA has been shown to be upregu-
lated in a cell line model of prostate cancer progression
involving acquisition of androgen independence [18].
Bladder and kidney carcinoma have been associated
with loss of ELF5 expression at the protein and RNA
levels [19, 20], whereas in endometrial carcinoma ELF5
upregulation is associated with higher disease stage
[21]. ELF5 gene rearrangements have been described in
several lung cancer cell lines [5], and the authors of a re-
cent case study described a ZFPM2-ELF5 fusion gene in
multicystic mesothelioma [22]; however, gene fusions do
not appear to be a major mechanism for deregulation of
ELF5, in contrast to other ETS factors, such as TMPRSS2-
ERG/ETV1 fusions in prostate cancer [23].
The breast is the most well-studied context for the role
of ELF5 in cancer, with microarrays showing increased
expression in basal-like subtypes and decreased expression
in luminal A/B and Erb-b2 receptor tyrosine kinase 2
(HER2)-overexpressing subtypes [24, 25], suggesting
subtype-specific effects. Transient ELF5 expression in cell
line models reduced proliferation, invasion, ER -driven tran-
scription and epithelial–mesenchymal transition [25, 26].
However, sustained increased ELF5 expression in some con-
texts is associated with disease progression, such as inendocrine-resistant breast cancers, reliant on elevated ELF5
for growth in cell line models, and the basal-like subtype of
breast cancer [25]. This illustrates the complexity and con-
textual dependence of transcriptional regulation.
It is becoming increasingly recognized that almost all
multiexon genes undergo alternative transcription (such
as alternative transcription start or termination sites)
and/or alternative exon splicing, increasing diversity of
protein structure and function [27]. Alternative transcrip-
tion events are also commonly deregulated in cancer, con-
tributing to tumor initiation and progression but also
providing potential cancer-specific therapeutic targets.
Importantly, different isoforms produced by the same
gene may have very different functions. One striking ex-
ample is vascular endothelial growth factor, which pro-
duces both proangiogenic and antiangiogenic isoforms
[28]. Early studies described tissue-specific differences in
ELF5 transcript isoform expression [6], but recent studies
have not distinguished between isoforms or have used a
single isoform for overexpression studies.
This study represents the first comprehensive analysis
of ELF5 expression at the isoform level, using RNA-
sequencing (RNA-seq) data from The Cancer Genome
Atlas (TCGA) for 6757 normal tissue and cancer samples.
The functional effects of ELF5 isoform expression in breast
cancer were also investigated using inducible cell line
models and a 116-gene quantitative polymerase chain
reaction (qPCR) panel, leading to unique insights into
the transcriptional functions of ELF5 and in particular
the role of the PNT domain.
Methods
RNA-sequencing analysis
RNA-Seq version 2 data for initial primary tumors and
solid tissue normal samples (where n ≥ 3) were down-
loaded from TCGA data portal (https://tcga-data.nci.nih.
gov/tcga/) [29–43], with institutional human research
ethics committee exemption. Samples with available RNA-
Seq version 2 data (August 2013 for breast and April 2014
for all other cancer types) were included. The RNA-Seq
version 2 TCGA pipeline for preprocessing of publicly
available data used MapSplice [44] for alignment and
RSEM [45] for quantitation. Non-normalized gene and
isoform data were downloaded from TCGA as RSEM
expected (“raw”) counts, unadjusted for transcript length,
and scaled estimates, adjusted for transcript length. Scaled
estimates were multiplied by 106 to obtain transcripts per
million (TPM) values. Normalized gene and isoform data
were downloaded from TCGA as quantile normalized
RSEM expected counts (unadjusted for transcript length),
with the upper quartile set at 1000 for gene data and 300
for isoform data.
A summary of all TCGA samples used in the analysis
is shown in Table 1. For breast cancer samples, PAM50
Table 1 Summary of all TCGA RNA-sequencing samples used in analysis
Tissue Cancer type TCGA acronym Normal samplesa Cancer samples
Bladder Bladder urothelial carcinoma BLCA 19 241






Cervix Cervical squamous cell carcinoma and
endocervical adenocarcinoma
CESC 3 185
Colon Colon adenocarcinoma COAD 41 261
Head/neck (including mouth and throat) Head and neck squamous cell carcinoma HNSC 43 497
Kidney Chromophobe KICH 25 66
Clear cell carcinoma KIRC 72 518
Papillary cell carcinoma KIRP 30 172
Liver Hepatocellular carcinoma LIHC 50 191
Lung Lung adenocarcinoma LUAD 58 488
Lung squamous cell carcinoma LUSC 50 490
Pancreas Pancreatic adenocarcinoma PAAD 3 85
Prostate Prostate adenocarcinoma PRAD 50 297
Rectum Rectum adenocarcinoma READ 9 91
Thyroid Thyroid carcinoma THCA 59 498
Uterus Uterine corpus endometrial carcinoma UCEC 24 158
Uterine carcinosarcoma UCS NAc 57
Adrenal gland Adrenocortical carcinoma ACC NA 79
Hematological Diffuse large B-cell lymphoma DLBC NA 28
Acute myeloid leukemia LAML 173
Brain Glioblastoma multiforme GBM NA 156
Lower grade glioma LGG 463
Ovary Ovarian serous cystadenocarcinoma OV NA 262
Skin Cutaneous melanoma SKCM NA 82
Bone/connective tissue/soft tissue Sarcoma SARC NA 103
TCGA The Cancer Genome Atlas
aNormal samples included where n ≥ 3
b65 samples included in differential expression analysis
cUterine corpus endometrioid carcinoma normal samples used as normal uterine samples for differential expression analysis
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status was used to generate a subtyped cohort of 515 pa-
tients and 59 matched normal samples [29, 46]. Six add-
itional normal samples, matching to tumors in the initial
cohort, were included in differential expression analyses.
Limma voom [47] was used for differential expression
analysis of gene-level RNA-seq data, with inputs as
non-normalized gene data (RSEM expected counts).
Filtering was applied to remove genes with low expres-
sion, keeping genes with counts >1 in at least n samples
(where n = number of samples in smallest group ofreplicates). The trimmed mean of M-values normalization
method [48] was applied, followed by differential ex-
pression analysis using Limma voom. All fold change
(FC) and false discovery rate (FDR) values reported
were generated by Limma voom analyses. Venn dia-
grams were created using online software (http://bio-
informatics.psb.ugent.be/webtools/Venn/), and
clustered heat maps were created using the R package
gplots [49]. As a comparison, differential expression
analysis was also carried out using edgeR [50–54] (see
Additional file 1: Methods).
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ELF5 isoforms 1, 2, and 3 were tagged with C-terminal
V5 (and short linker sequence), cloned into the pHUSH-
ProEx vector [55], and used as a retrovirus. T47D-EcoR
and MDA-MB-231-EcoR cells stably expressing ecotropic
receptor were infected with pHUSH-ELF5 retrovirus and
selected using puromycin. To generate clonal cell lines,
stable cell line pools were plated at low density in 96-well
plates.
Cell lines and treatments
All cell lines were obtained from the American Type
Culture Collection (Manassas, VA, USA) and were main-
tained in RPMI medium supplemented with insulin and
10 % tetracycline-free fetal bovine serum (Clontech
Laboratories, Mountain View, CA, USA). Puromycin
was added at a concentration of 1 μg/ml. Doxycycline
(Dox) was added at a concentration of 0.1 μg/ml daily to
induce protein expression.
Cell number assay
Cell number was quantified using a spectrophotometric
assay. Cells were incubated with 16 % trichloroacetic
acid and stained with 10 % Diff-Quik II solution (Lab
Aids, Narrabeen, Australia). 10 % acetic acid was added
to dried plates, and 100 μl of solution from each well
was added to a 96-well plate, which was read at 595 nm.
Absorbance readings were transformed to natural loga-
rithms, and values from three wells (single experiment)
were averaged for each time point. The minus Dox and
plus Dox slopes for each cell line were compared using
linear regression analysis.
Western blot analysis
Protein was prepared in NuPAGE Sample Buffer and
Reducing Agent (Life Technologies, Carlsbad, CA, USA)
using 10 μg (estrogen-related blots), 65 μg (V5 blot,
T47D-ELF5-isoform 2-V5) or 25 μg (V5 blots, all other
lines) per lane. Samples were separated on precast 15-well
4–12 % Bis-Tris (estrogen-related blots) or 10-well 10 %
Bis-Tris (V5 blots) polyacrylamide gels (Life Technologies),
transferred to polyvinylidene fluoride membrane, blocked
in 5 % skim milk, and incubated overnight at 4 °C in
primary antibody. Secondary horseradish peroxidase–
conjugated antibody was added 1:2000 in 5 % skim milk
(anti-mouse, NA931V, anti-rabbit, NA934V; GE Healthcare
Life Sciences, Little Chalfont, UK). Proteins were detected
using enhanced chemiluminescence solution (Western
Lightning Plus; PerkinElmer, Waltham, MA, USA) and
x-ray film (Fujifilm, Tokyo, Japan). Primary antibodies
used were anti-V5 (sc-58052, 1:500–1:1000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-transducin-
like enhancer of split 1 (anti-TLE1) (ab183742, 1:1000;
Abcam, Cambridge, UK), anti-ERα (sc-8005, 1:1000;Santa Cruz Biotechnology), anti-Forkhead box A1 (anti-
FOXA1) (sc-101058, 1:1000, Santa Cruz Biotechnology),
and anti-β-actin (AC-15, 1:20,000; Sigma-Aldrich, St. Louis,
MO, USA).
Transient retroviral infection
ELF5 isoform 3 was tagged with C-terminal hemagglutinin
(HA), cloned into the pQCXIH vector (Clontech) and used
as a retrovirus. MDA-MB-231-EcoR-pHUSH-ELF5-
isoform 2-V5 Clone 7 cells were infected with ELF5-
isoform 3-HA/empty vector retrovirus diluted 1:4. No
pQCXIH selection pressure was applied.
Immunofluorescence
Cells were infected with pQCXIH retrovirus in eight-well
Lab-Tek II chamber slides (Thermo Scientific, Waltham,
MA, USA) and allowed to recover for 24 h. Dox /vehicle
treatment (lasting 24 h) was then commenced. Cells were
fixed with 4 % paraformaldehyde diluted in PHEM buffer
(60 mM piperazine-N,N′-bis(2-ethanesulfonic acid)
(PIPES), 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesul-
fonic acid (HEPES), 1 mM ethylene glycol tetraacetic acid
(EGTA), 2 mM MgCl2, pH 6.9), permeabilized with 0.5 %
Triton X-100, blocked with 10 % donkey serum/PHEM so-
lution, and incubated overnight at 4 °C in primary anti-
body. Secondary antibodies were added at 1:200, and
coverslips were applied using Duolink In Situ Mounting
Medium with 4′,6-diamidino-2-phenylindole (DAPI)
(Olink Bioscience, Uppsala, Sweden). Imaging was
performed on a Leica DM5500 microscope (Leica
Microsystems, Wetzlar, Germany). Antibodies (in 10 %
donkey serum/PHEM solution): anti-V5 (sc-58052, 1:200;
Santa Cruz Biotechnology), anti-HA (3724, 1:800; Cell
Signaling Technology, Danvers, MA, USA), and donkey
anti-mouse Alexa Fluor 647 and donkey anti-rabbit
Alexa Fluor 555 conjugates (1:200; Molecular Probes/
Thermo Fisher Scientific, Eugene, OR, USA).
Quantitative PCR
RNA was extracted using the RNeasy Mini Kit with
DNase treatment (Qiagen, Valencia, CA, USA) and quanti-
fied using the NanoDrop spectrophotometer (NanoDrop
Products, Wilmington, DE, USA). Complementary DNA
(cDNA) was made using the High-Capacity cDNA Reverse
Transcription Kit (Life Technologies) with ribonuclease in-
hibitor (Promega, Madison, WI, USA). All qPCRs were
run on an ABI 7900 qPCR machine (Applied Biosystems,
Foster City, CA, USA), using standard TaqMan cycling
conditions or Roche Universal Probe Library (UPL) proto-
col with two or three technical replicates per sample (see
also Additional file 1).
For the clonal cell line time-course qPCR (Fig. 6f),
0.5 μg of RNA per 20 μl of cDNA reaction and ELF5
(Hs01063022_m1) and glyceraldehyde 3-phosphate
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gene panel, cell lines were treated for 48 h with Dox or
vehicle. cDNA reactions were scaled to 100 μl and 2.5 μg
RNA. Roche UPL assays were designed using the online
Roche ProbeFinder software. All assays are detailed in
Additional file 2.
Results were analyzed using SDS 2.4 (Life Technologies)
and qbase + software (Biogazelle, Gent, Belgium) [56].
Paired t tests were used to calculate p values, comparing
-Dox and +Dox samples (three or four pairs per cell line
group). Correction for multiple comparisons was per-
formed using the Benjamini-Hochberg procedure, setting
the FDR at 0.10 [57].
Results
ELF5 isoforms are differentially expressed in normal tissues
There are four ELF5 transcript variants in the National
Center for Biotechnology Information RefSeq database
[58], predicted to produce four unique proteins (Fig. 1).
The two full-length transcripts (isoforms 1 and 2) use al-
ternative promoters, resulting in unique first exons and
proteins that differ by only ten N-terminal amino acids.
Two additional transcripts (isoforms 3 and 4) are produced
by splicing of exons 4 (±5) from each of the full-length
transcripts, producing proteins that lack the PNT domain
but retain the ETS domain. An additional transcript
(isoform 5), described by the GENCODE Consortium [59],Fig. 1 ELF5 isoforms are produced by alternative promoter use and splicin
ETS E26 DNA-binding domain, PNT Pointed domain, bp base pairs, aa aminis a variant of isoform 2 terminating at an extended exon 4.
This type of intronic extension (“bleeding exon”) is often
associated with incompletely processed transcripts [60],
and it is unclear whether this transcript produces a protein
product (which would lack the ETS domain).
RNA-seq data from TCGA were analyzed to quantify and
compare ELF5 isoforms in normal and cancer tissues
[29–43]. A summary of all TCGA samples analyzed is shown
in Table 1. TCGA preprocessed data include ELF5 isoforms
1, 2, and 3 as annotated by RefSeq, as well as isoform 5. Due
to the reference annotation used by TCGA, there are no data
for ELF5 isoform 4. The transcripts and protein products are
summarized in Fig. 1, and a cross-database comparison is
shown in Additional file 1: Figure S1.
ELF5 expression was highest in epithelial tissues such
as the breast, kidney, lung, prostate, and bladder (Fig. 2a).
The breast was one of the highest ELF5-expressing tis-
sues in the body. Isoform 1 and 2 expression was highly
tissue-specific (Fig. 2b), indicating alternative promoter
use in different tissues.
Data in Fig. 2a and b were quantile-normalized by the
TCGA pipeline, allowing comparison of abundance of a
particular transcript (such as total ELF5) between samples.
However, longer transcripts will generate more sequen-
cing reads, making quantitative comparison of transcripts
of different lengths problematic. To overcome this, the
proportional measure TPM may be used. TPM is ang. RefSeq and GENCODE transcripts with protein products are shown.
o acids, ext extended
Fig. 2 E74-like factor 5 (ELF5) isoforms are differentially expressed in normal tissues. Plotted values are for individual RNA-sequencing samples
from The Cancer Genome Atlas, and error bars represent the mean with 95 % confidence interval. a ELF5 gene expression in 13 normal tissues
(quantile normalized counts). b ELF5 isoform expression in selected normal tissues (quantile normalized counts). c Mean ELF5 levels (transcripts
per million, TPM) in normal tissues. Relative isoform contributions are shown within each bar. Numbers in parentheses indicate samples per group.
d Mean ELF5 gene and isoform expression in normal tissues. All values are TPM, except for column 1, which is the quantile-normalized count. Isoform
ratios in the final two columns were calculated using mean TPM values
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should be noted that values are not technically compar-
able between samples, particularly when the composition
of the total mRNA pool may be quite different (for
example, when comparing different tissues). For this
reason, data are shown for both quantile-normalized
(between-samples–normalized) (Fig. 2b) and TPM-
normalized (within-sample–normalized) (Additional file 1:
Figure S2b). As the lengths of ELF5 transcripts are not
widely different, ranging from 2039 to 2466 base pairs, the
data plots are in fact similar.
Since TPM is a proportional measure, the relative abun-
dances of transcripts of different lengths within samples
can be compared. The mean TPM values for ELF5 iso-
forms are shown in Fig. 2c and d. Breast, bladder, head/
neck, lung, and prostate all expressed isoform 2 as their
main transcript (median percentage 82.1–95.2 %) (Additional
file 1: Figure S2a), while the kidney expressed mainly isoform
1 (median 91.8 %). All tissues examined expressed, on aver-
age, more full-length isoform 2 than the shorter isoform 3.ELF5 expression is significantly altered in cancer
In malignancy, ELF5 expression was significantly altered
compared with normal tissues, as shown by Limma
voom differential gene expression analysis (Fig. 3a). In
the cervix, colon, rectum, and uterus, cancer was associ-
ated with an increase in ELF5 level, driven mainly by an
increase in isoform 2 and, to a lesser extent, isoform 3
(Fig. 3b). Conversely, there was almost complete sup-
pression of ELF5 expression in three kidney carcinoma
subtypes. ELF5 expression was also significantly de-
creased in head and neck, lung, and prostate cancer
(Fig. 3c). In both lung carcinoma subtypes, there was a
large variation in ELF5 levels, suggesting possible molecu-
lar subtype-specific expression patterns, similar to the
breast. ELF5 expression was largely unchanged (or filtered
from analysis due to low expression) in the tissues shown
in Fig. 3d. The cancer types shown in Fig. 3e exhibited
very low levels of ELF5 expression but had no normal
tissue samples available for comparison. Analysis of addi-
tional RNA-seq normal tissue datasets (Genotype-Tissue
Fig. 3 (See legend on next page.)
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Fig. 3 E74-like factor 5 (ELF5) expression is significantly altered in cancer. The Cancer Genome Atlas (TCGA) RNA-sequencing (RNA-seq) data for
25 cancer types (pink background) are shown, with normal tissue comparisons (green background) where available. Plotted values are for individual
TCGA RNA-seq samples, and error bars represent the mean with 95 % confidence interval. TCGA cancer acronyms are used (see Table 1). a ELF5
gene expression (normalized counts) for 25 cancers with normal tissue comparisons where available. Fold changes and false discovery rates
(FDRs) from Limma voom analysis are shown, with green values in bold indicating significant downregulation and red values in bold significant
upregulation compared with normal (FDR < 0.05). Filt. indicates gene filtered from Limma voom analysis due to low expression. b ELF5 isoform expression
in normal and cancer samples (with ELF5 gene upregulation in cancer). c ELF5 isoform expression in normal and cancer samples (with ELF5
gene downregulation in cancer). d ELF5 isoform expression in normal and cancer samples (unchanged or filtered ELF5). e ELF5 isoform expression in
cancer samples without available normal samples (normal samples≤ 2). Note smaller scale on y-axis
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firmed that the normal adrenal gland, brain, leukocytes/
whole blood, lymph node, ovary, and skeletal muscle all
had very low or absent ELF5 expression (Additional file 1:
Figure S3a and b). Skin was the only exception from this
group of tissues demonstrating moderate ELF5 expression
consistent with previous studies of differentiated keratino-
cytes [6].
Differential expression analysis was also carried out
using edgeR. Overall, the results from Limma voom and
edgeR were similar. The edgeR FC and FDR values are
presented in Additional file 1: Figure S4a for comparison.
ELF5 expression is altered in breast cancer in a
subtype-specific manner
Comprehensive analysis of RNA-seq incorporating mo-
lecular subtype was undertaken for 515 breast cancer
patients. In the luminal A, luminal B, and HER2 sub-
types, ELF5 was significantly downregulated (fold change
0.02–0.13 compared to normal), while in the basal sub-
type there was a strong trend for increased ELF5 expres-
sion (1.96-fold compared with normal, FDR 0.053 in
Limma voom analysis, 1.99-fold compared with normal,
FDR 0.0008 in edgeR analysis) (Fig. 4a and Additional file
1: Figure S4b). There was no clear relationship between
ELF5 expression and American Joint Committee on
Cancer stage (Additional file 1: Figure S5).
This analysis was extended to the isoform level by
examining the contribution to total ELF5 (based on
mean TPM) for each isoform (Fig. 4b). Normal-like sam-
ples were excluded due to low sample numbers. The
main isoform expressed in all breast cancer subtypes
was isoform 2. In the luminal A, luminal B, and HER2
subtypes, all ELF5 isoforms were decreased in cancer
compared with normal (Fig. 4c). Conversely, in the basal
subtype, three of four isoforms were upregulated, with
isoform 3 having a relatively larger fold change.
The percentage contributions of each isoform to total
ELF5 were also analyzed (Fig. 4d and e). The normal breast
showed a tight range of expression, while in cancer, particu-
larly for isoforms 2 and 3, this was broadened (Fig. 4d). The
high variability in isoform 3 percentage values in the cancer
samples led to an increased mean percentage in all sub-
types. Median values demonstrated a smaller, although stillincreased, isoform 3 percentage in cancer, while the median
isoform 2 percentage remained fairly constant across nor-
mal and cancer samples.
Within this cohort, 65 patients had matched tumor and
normal samples that could be directly compared (Fig. 4f
and Additional file 1: Figure S4c). The luminal A, luminal
B, and HER2 groups showed a highly significant decrease
in ELF5 level in both the Limma and edgeR analyses. In the
basal subgroup, there was an upward but variable trend.
Expression of other ETS family members is also altered in
breast cancer, with the basal subtype having a distinct
ETS expression profile
The same cohort of patients was used to examine expres-
sion of other members of the ETS transcription factor fam-
ily. RNA-seq data showed that a large number of ETS
factors were expressed in the normal breast. Average TPM
values (which take into account transcript length) for ETS
factors in the normal breast ranged from 0.02 to 117.7.
Several ETS factors had very low expression (<2 TPM), in-
cluding FEV, SPIC, ETV2, ETV3L, and SPIB. The most
highly expressed ETS factors in the normal breast were
EHF, ELF3, SPDEF, and ELF5 (Additional file 1: Figure S6).
ETS factor expression was significantly altered in breast
cancer, as shown by Limma voom differential expression
analysis. In the first (unpaired) analysis, samples from each
molecular subtype, excluding normal-like, were compared
with the common set of 65 normal breast samples, allow-
ing analysis of larger sample sets. In the second (paired)
analysis, normal and subtyped tumor samples from the
same patient were compared, allowing for more rigorously
matched comparisons but limited by smaller sample num-
bers. ETS factors with low expression (three to five per
subtype) were filtered from the analysis.
Of the 25 ETS factors included in the unpaired ana-
lysis, 24 were significantly altered in at least 1 subtype,
with 14 common to all subtypes (Fig. 5a). Within these,
13 were altered in the same direction (5 up and 8 down
in the tumor compared with normal), while SPDEF was
oppositely regulated in basal compared with other sub-
types. In the paired analysis, 21 ETS factors were signifi-
cantly altered in at least 1 subtype, with 3 ETS factors
common to all subtypes (SPDEF, ERG, and ETS2) and an
additional 8 common to 3 of 4 subtypes (Fig. 5b). ELF5
Fig. 4 (See legend on next page.)
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Fig. 4 E74-like factor 5 (ELF5) expression is altered in breast cancer in a subtype-specific manner. a ELF5 gene (left) and isoform (right) expression
(quantile-normalized counts) for normal breast and breast cancer subtypes. Plotted values are for The Cancer Genome Atlas RNA-sequencing (RNA-seq)
samples, and error bars represent the mean with 95 % confidence interval. Fold change (FC) and false discovery rate (FDR) from Limma voom analysis
are shown for ELF5 gene data, with green values in bold indicating a significant downregulation and red values in bold a significant upregulation
compared with normal (FDR < 0.05). Nonbold green or red values indicate FDR of 0.05–0.10. b Mean ELF5 levels in transcripts per million (TPM)
in normal breast and breast cancer, excluding normal-like, with 95 % confidence interval. Relative isoform contributions shown within each
bar. Numbers in parentheses indicate samples per group. c Mean ELF5 expression values at the gene and isoform levels (columns 1–6), isoform
fold changes in cancer compared with normal (columns 7–11), and isoform ratios (columns 12 and 13). All values are TPM, except for column 1, which
is the quantile-normalized count. Ratios were calculated using mean TPM values. d Box-and-whisker plot representing isoform percentage of total ELF5
in normal breast and cancer. Box 25–75th percentile, horizontal line median, error bars 10th–90th percentile, circles outliers. e Mean (left) and median
(right) isoform percentage values for normal breast and cancer. f ELF5 levels (quantile-normalized count) for patients with matched normal and cancer
samples, categorized according to tumor molecular subtype. Six extra matched normal samples were included, for a total of 65 pairs. Plotted values
represent individual samples, with samples from the same patient connected with a line. FC and FDR from paired Limma voom analysis are shown,
with green values indicating a significant downregulation compared with normal (FDR < 0.05). Numbers in parentheses indicate sample pairs per group
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change in the luminal A, luminal B, and HER2 subtypes
in both unpaired and paired analyses.
Compared with other subtypes, the basal group showed
a number of unique ETS factor expression changes. To
further explore this, the Limma t statistics for all ETS fam-
ily members (tumor compared with normal) were plotted
on a clustered heat map (Fig. 5c, unpaired, and Fig. 5d,
paired). The basal subtype showed a distinct expression
profile and clustered separately from the other subtypes in
both paired and unpaired analyses, highlighting the poten-
tial for the ETS transcription factor family to exert a
unique transcriptional influence in this subtype. Similar
results were obtained with unpaired and paired edgeR
analyses (Additional file 1: Figure S7).
Several ETS family members with significant changes
in expression were selected to visualize the results of the
breast cancer differential expression analyses. The normal-
ized counts for ERG (downregulated), ETV7 (upregulated),
and SPDEF (differentially regulated) are shown in Fig. 5e.
Direct comparison of matched normal and tumor samples
is shown in Fig. 5f. Interestingly, SPDEF showed the in-
verse expression pattern of ELF5. The normalized counts
for the entire ETS factor family, with the results of the
Limma voom and edgeR differential expression analysis,
are shown in Additional file 1: Figure S8.
Alterations in cell line ELF5 isoform levels result in a
similar phenotype, characterized by decreased cell
number, decreased estrogen-related proteins, and nuclear
localization
TCGA data showed an increased diversity of ELF5 isoform
expression in cancer compared with the normal breast;
therefore, the expression levels and effects of ELF5 isoform
expression were examined in vitro to determine if this was
of functional consequence.
ELF5 expression in a panel of breast cancer cell lines
was analyzed by qPCR and Western blotting (Additional
file 1: Figure S9a and d). Three cell lines (T47D, BT474,and HCC1187) expressed high levels of ELF5 protein
(Additional file 1: Figure S9d), with the size of the main
band consistent with isoform 2. A possible band represent-
ing isoform 3 was seen in the HCC1187 cell line; however,
interpretation was difficult due to high background.
Clonal cell lines were constructed with a Dox-
inducible expression vector containing a single ELF5 iso-
form, tagged with C-terminal V5. The luminal cell line
T47D (ER+/PR+/HER2−) was chosen to examine the effect
of isoforms in the context of relatively high endogenous
ELF5 expression, testing the hypothesis that isoforms lack-
ing the PNT domain might exert a dominant-negative ef-
fect on full-length isoform function. A second claudin-low
cell line, MDA-MB-231 (ER−/PR−/HER2−), was chosen as
it expresses no endogenous ELF5, allowing the effects of
each isoform to be determined in the absence of poten-
tial competitive isoform interactions.
Over a 5-day time course, induced expression of iso-
forms 1, 2, and 3 all resulted in a significantly decreased
growth rate in T47D cells, with no change in the empty
vector control (Fig. 6a). Representative light microscopic
images for T47D lines (Fig. 6b) demonstrate decreased
cell number and increased detached cells (additional im-
ages shown in Additional file 1: Figure S9e and f). A
similar but less pronounced decrease in growth rate was
also seen with induction of isoform 2 and isoform 3 in
the MDA-MB-231 lines (Fig. 6c). It has previously been
shown that the mechanisms underlying this phenotype
for ELF5 isoform 2 include G1 arrest, increased apop-
tosis, and reduced adhesion proteins [25].
In the T47D lines, each isoform caused a decrease in
ERα protein and pioneer factors FOXA1 and TLE1, required
for ER–chromatin interactions [61, 62] (Fig. 6d). The effects
on FOXA1 and TLE1 were also seen in the MDA-MB-231
lines, in the absence of detectable ERα (Fig. 6e). Dox -indu-
cible ELF5 mRNA expression was shown by qPCR (day 5)
(Fig. 6f). V5 antibody Western blot analysis confirmed
ELF5-V5 protein expression and also illustrated the size dif-
ference between isoforms 2 and 3 (Fig. 6g).
Fig. 5 (See legend on next page.)
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Fig. 5 Expression of other E26 transforming sequence (ETS) family members is also altered in breast cancer, with the basal subtype having a distinct
ETS expression profile. The Cancer Genome Atlas RNA-sequencing (RNA-Seq) Limma voom differential expression analysis data for ETS family members.
a Venn diagram showing number of ETS family members significantly altered in breast cancer subtypes compared with normal (false discovery rate
[FDR] < 0.05). All subtypes were compared with a common set of 65 normal samples (unpaired analysis). Genes altered in all four subtypes are listed
(red = upregulation, green = downregulation, purple= differentially regulated in basal subtype compared with other subtypes). b Venn diagram showing
number of ETS family members significantly altered in breast cancer subtypes compared with normal (FDR < 0.05), using paired normal and tumor
samples from the same patient. Genes altered in at least three of four subtypes are listed, with color-coding as above. c Clustered heat map of
ETS factor Limma voom t statistic, comparing tumor samples to the common set of 65 normal samples. Legend is shown next to (d). Rows
are sorted by luminal B values (smallest to largest), and columns are sorted according to clustering. Numbers in parentheses are samples per
group. d Clustered heat map of Limma voom t statistic, comparing paired normal and tumor samples, with sorting as above. Numbers in
parentheses are sample pairs per group. e Expression of ERG, ETV7, and SPDEF for normal breast (green background) and breast cancer
subtypes (pink background). Plotted values are for individual samples (normalized counts), and error bars represent the mean with 95 %
confidence interval. Fold change (FC) and FDR from unpaired Limma voom differential expression analysis are shown, with green indicating a significant
downregulation and red a significant upregulation compared with normal (FDR < 0.05). f ERG, ETV7, and SPDEF levels for a 65 patients with matched normal
and cancer samples. FC and FDR from paired Limma voom differential expression analysis are shown, with color-coding as above (FDR< 0.05). Numbers in
parentheses are sample pairs per group
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subcellular location of ELF5 isoforms when expressed in
isolation and when coexpressed. MDA-MB-231 cells with
Dox -inducible ELF5-isoform 2-V5 expression were used,
with transient retroviral infection of an ELF5-isoform
3-HA vector. This allowed manipulation of isoform 2
and isoform 3 levels within the same cell. Figure 6h
(top row) shows MDA-MB-231-ELF5-isoform 2-V5
cells treated with Dox to induce expression, as well as
transient infection of a control pQCXIH vector. There
was strong nuclear V5 staining and no HA staining. In
row 2, cells were treated with Dox to induce ELF5-
isoform 2-V5 and also infected with isoform 3-HA.
Both isoform 2 (V5) and isoform 3 (HA) localized to
the nucleus, and there was no cytoplasmic redistribu-
tion seen in the cells that expressed both isoform 2 and
isoform 3 (indicated by arrows), an effect that has been
reported previously for ETS1 isoforms [63].
ELF5 isoforms have a similar transcriptional effect in T47D
and MDA-MB-231 cell lines
A panel of 116 genes was examined by qPCR to compare
the transcriptional effects of ELF5 isoforms. Previously
published microarrays and ELF5/V5 chromatin immuno-
precipitation with massively parallel DNA sequencing [25]
were used to identify genes and pathways regulated by
ELF5 isoform 2 in luminal cell lines. The assays are de-
scribed in Additional file 2, with an outline of the experi-
mental workflow shown in Additional file 1: Figure S10.
The pHUSH clonal cell lines were selected on the
basis of similar qPCR levels of ELF5 isoform induction.
Figure 7a shows the ELF5 level with Dox relative to the
without Dox control for each individual cell line. To
compare baseline (without Dox) variability, values were
also normalized to the lowest ELF5 value (Fig. 7b). Base-
line variability was minimal in the T47D lines; however,
expression ranged from 1.0- to 2.3 in the MDA-MB-231
isoform 3 lines and from 4.7 (clone 6) to 28.0 (clone 1)in the isoform 2 lines. This variation is most likely due
to slight “leakiness” of the pHUSH vector, leading to
low-level ELF5 expression (undetectable by V5 Western
blotting) in the absence of Dox.
T47D and MDA-MB-231 clonal cell lines were treated
with Dox or vehicle for 48 h to induce ELF5 isoform
expression. Initially, two clones per parental cell line
were used. A selection of 27 genes was then repeated in
1 or 2 further clones, giving a total of 3 or 4 clonal lines
(biological replicates) per parental line (Additional file 1:
Table S1). The heat maps in Fig. 7 show the log10 FC for
each gene when ELF5 isoform expression is induced
(+dox) compared with baseline (−dox).
Overall, the pattern of change was fairly similar, regard-
less of which ELF5 isoform was expressed. The genes with
the strongest absolute FC (>3 in any T47D line or >2 in
any MDA-MB-231 line) showed a particularly consistent
pattern of change (Fig. 7c). Expression changes were
greater in the T47D than in the MDA-MB-231 cell lines.
Genes were also analyzed in functional categories
(Fig. 7d). Apoptosis-related genes showed consistent
changes corresponding to an increase in apoptosis, such
as upregulation of apoptosis-promoting genes, including
DDIT3, PUMA, NOXA, TP53, and various caspases, as
well as downregulation of apoptosis-inhibiting genes such
as BCLX and BCL2. The changes in cell cycle genes were
weaker, although still generally consistent, with upregula-
tion of cell cycle inhibitors such as RB1CC1 and TP53
and downregulation of cell cycle–promoting genes such
as cyclins D1, B1, A2, and E2 and associated kinases
CDK1/2. However, the pattern of change was not en-
tirely congruent with inhibition of the cell cycle, with
upregulation of the cyclin D–associated CDK6 and
downregulation of the cell cycle inhibitor CDKN2C
(p18). Changes in mRNA expression for key genes asso-
ciated with estrogen action, such as ESR1, FOXA1,
GATA3, and GREB1, were relatively small and variable
(Fig. 7d), in contrast to results at the protein level,
Fig. 6 Alterations in cell line E74-like factor 5 (ELF5) isoform levels result in a similar phenotype, characterized by decreased cell number, decreased
estrogen-related proteins, and nuclear localization. a and c Time course of T47D (a) and MDA-MB-231 (c) pHUSH clonal cell line growth with
and without doxycycline (Dox) over 5 days. Graphs show the natural logarithm (Ln) of spectrophotometric assay absorbance value (y-axis)
plotted against day (x-axis). p values compare minus Dox and plus Dox slopes for each cell line. One experiment is shown. b Representative
light microscopic images of T47D cells with and without doxycycline, taken at day 4. d Western blots for estrogen-related proteins from T47D
time courses, days 0–5. e Western blots for estrogen-related proteins from MDA-MB-231 time courses, days 2–5. f Quantitative polymerase chain reac-
tion for ELF5 (day 5 time course samples) minus and plus Dox. g Western blots for V5 at days 4 and 5 minus and plus Dox, 65 μg per lane (T47D-ELF5-
isoform 2-V5 line) or 25 μg per lane (all others). Bottom panel shows representative samples from MDA-MB-231 cell lines, demonstrating size difference
between isoforms 2 and 3. h Immunofluorescent images of MDA-MB-231-ELF5-isoform 2-V5 clone 7 cells. Blue= nuclei (4′,6-diamidino-2-phenylindole
[DAPI]), red = V5, green = hemagglutinin (HA). Arrows mark cells with double-isoform 2 and 3 expression
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Fig. 7 (See legend on next page.)
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Fig. 7 E74-like factor 5 (ELF5) isoforms have a similar transcriptional effect in T47D and MDA-MB-231 cell lines. a ELF5 expression measured by
quantitative polymerase chain reaction (qPCR) at 48 h for T47D clonal cell lines (top) and MDA-MB-231 clonal cell lines (bottom). Assay detects all
ELF5 isoforms. Values are the mean calibrated normalized relative quantity (CNRQ) with standard error. Results relative to the minus doxycycline
(−Dox) control (set at 1) for each cell line. b ELF5 expression measured by qPCR at 48 h for T47D clonal cell lines (top) and MDA-MB-231 clonal
cell lines (bottom) used in the qPCR panel. Assay detects all ELF5 isoforms. Values are the mean CNRQ with standard error. Results relative to the
sample with the lowest ELF5 value (set at 1), which is T47D-ELF5-isoform 2-V5 clone 8 (T47D lines) and MDA-MB-231-ELF5-isoform 3-V5 clone 22
(MDA-MB-231 lines). c Heat map showing genes (from 116-gene qPCR panel) with absolute fold change >3 (any T47D line) or >2 (any MDA-MB-
231 line). Two clonal cell lines were tested per group. All heat maps use the legend shown in (e) and represent the log10 fold change (capped
at −1 and +1) of the plus Dox quantity compared with the minus Dox quantity as measured by qPCR. Gray indicates gene was not detectable by
qPCR in minus and/or plus Dox samples. d Functional categorization of selected genes from 116-gene qPCR panel. Some genes are rep-
resented more than once due to multiple functions. e Heat map showing genes (from 27-gene qPCR panel) with absolute fold change >3 (any
T47D line) or >2 (any MDA-MB-231 line). Results shown for three or four clonal lines per group. f Functional categorization of selected genes
from 27-gene qPCR panel. g Heat map representing the mean log10 fold change per group for all genes in the 27-gene panel, as well as ELF5.
Significant p values are shown where false discovery rate (FDR) is <0.10. Some p values (nonbold) are >0.05, although FDR for these values is <0.10.
Nonsignificant p values (FDR >0.10) are not shown
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FOXA1 with all ELF5 isoforms.
The results were substantiated using 1 or 2 further
clones per parental cell line and 27 genes from the ori-
ginal panel (Fig. 7e and f). The average FC for each par-
ental cell line group (consisting of three or four clonal
cell lines) was calculated, and this is shown in the heat
map in Fig. 7g with corresponding significant p values
(FDR < 0.10). Although the pattern of change was gener-
ally consistent, there were some interesting differences.
First, FOXA1 expression in the T47D lines exhibited a
mostly downward trend, although there were no statisti-
cally significant changes. Conversely, in the MDA-MB-
231 lines, FOXA1 mRNA increased (significant only in
the isoform 2 group); again, this is in contrast to the
protein results shown for the MDA-MB-231 lines in
Fig. 7g. Second, there was only one case in the T47D
lines (and none in the MDA-MB-231 lines) in which a
gene was altered in statistically significant opposite di-
rections by different ELF5 isoforms. This gene, GATA3,
was upregulated by isoform 3 and downregulated by iso-
form 2, although the changes were relatively small. In
fact, 20 of 27 genes in the T47D lines showed a statisti-
cally significant change in the same direction with each
of the 3 isoforms, pointing toward the overall consistency
of the transcriptional effect of ELF5 isoforms.
Discussion
This study is the first detailed analysis of ELF5 isoform
expression and function, extending previous ELF5
Northern blot analysis, immunohistochemistry, and
microarray studies [5, 6, 16, 25] to the isoform level using
6757 sequenced normal and cancer samples. The kidney
appears to be unique in being the only tissue examined to
express isoform 1 as its dominant isoform, expanding
on the initial Northern blot analysis–based descriptions
of ELF5 isoforms [6]. In breast cancer, ELF5 alterations
were subtype-specific, with the basal subtype demonstrat-
ing unique ELF5 isoform expression changes. Despitedifferences in protein domains, the in vitro phenotypic
and transcriptional effects of increased ELF5 isoform ex-
pression were similar. This suggests that ELF5 action is
regulated in various tissues by tissue-specific alternative
promoter use rather than by differences in the transcrip-
tional activity of the isoforms.
In cancer, ELF5 expression is frequently altered. The
kidney, one of the highest ELF5-expressing tissues,
showed a dramatic decrease in ELF5 level in cancer.
ELF5 has been characterized as a tumor suppressor in
the kidney and bladder [19, 20], and this may restrict kid-
ney carcinomas to non-ELF5–expressing cells of origin. In
other tissues, cancer was associated with an aberrant in-
crease in ELF5 expression, as seen in the cervix, colon,
rectum, and uterus. This may indicate an oncogenic role
for ELF5 in these tissues or broader genomic deregulation,
such as DNA hypomethylation, a hallmark of the cancer
genome [64]. The mechanisms regulating ELF5 in differ-
ent tissues and in cancer have not been widely studied;
however, in the early embryo and the developing mam-
mary gland, ELF5 regulation of lineage specification is
associated with promoter methylation status [65, 66].
Increased ELF5 promoter methylation has also been
demonstrated in bladder carcinoma [19]. These studies
establish DNA methylation as an important epigenetic
mechanism regulating ELF5 expression, with possible
aberrant methylation in cancer.
The normal human breast expresses relatively high levels
of ELF5, with subtype-specific alterations in cancer. High
ELF5 has been shown to maintain the ER− basal pheno-
type, paralleling the normal developmental role of specifi-
cation of the ER− alveolar lineage [25]. In all breast cancer
subtypes, there was a broader distribution of ELF5 isoform
expression. Increased variability of isoform distribution
(“transcriptome instability”) is a known phenomenon
and is proposed as a molecular hallmark of cancer [67, 68].
A recent study identified 244 cancer-associated isoform
“switches” involving consistent changes in the most abun-
dant isoform [69]. An ELF5 isoform switch has not been
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study, which showed an inconsistent pattern of isoform ex-
pression variation. Although not consistently identified,
this does not mean that ELF5 isoform switches do not play
an important role in the subset of patients in which they
occur.
Other ETS transcription factors have also been shown
to be important in breast cancer. Extension of RNA-seq
analysis to the entire ETS family revealed a number of
cancer-associated expression changes. The ETS family as
a whole has previously been studied in breast cancer at
the qPCR level in mouse models [70] and human cell
lines [71], although the present study is the first, to our
knowledge, to include examination of the expression of
the entire human ETS family in both the normal breast
and subtyped breast cancer samples using RNA-seq data.
The normal human breast expressed a diverse range of
ETS factors. Compared with the normal breast, the
basal-like subtype showed a distinct pattern of ETS fac-
tor expression changes, with several ETS factors chan-
ging in the opposite direction in basal compared with
other subtypes. ELF5 and SPDEF were the most striking
examples of this phenomenon. SPDEF is also a luminal
epithelial lineage-specific transcription factor in the breast
and has been shown to promote the survival of ER+ breast
cancer cells [72]. The inverse relationship seen between
these two transcription factors in breast cancer is intri-
guing and may well have a parallel during normal mam-
mary development.
Finally, the phenotypic and transcriptional effects of
isoforms 1, 2, and 3 were found to be similar in indu-
cible cell line models. This was unexpected, as the PNT
domain in murine ELF5 has previously been shown to
have strong transactivation activity [12]. In many proteins,
SAM and/or PNT domains act as protein–protein inter-
action modules, an important mechanism of biological
specificity for ETS factors, which often bind only weakly
to DNA in the absence of binding partners or posttransla-
tional modifications [3, 12]. The importance of the PNT
domain is also shown by other ETS family members in
which removal of the PNT domain significantly alters
protein function. The endogenous ETS1 isoform p27,
for example, lacks the PNT and transactivation domains
and negatively regulates full-length ETS1 by competing
for DNA-binding sites and promoting its translocation
from the nucleus to the cytoplasm [63]. Although this
splicing event is similar to those that occur to produce
ELF5 isoforms 3 and 4, it appears that ELF5 isoform 3
can alter gene transcription in a very similar way to the
full-length isoforms. In addition, there was no subcellular
relocation of full-length isoform 2 seen when isoform 3
was coexpressed. Interestingly, however, while exogenous
ELF5 localized to the nucleus in this study, cytoplasmic
ELF5 staining is seen in some human breast cancersamples and is a predictor of outcome [73]. This indicates
that endogenous ELF5 can localize to the cytoplasm and
that this has functional significance in breast cancer. A po-
tential nuclear export sequence exists in the ETS domain
of ELF5 (amino acids 165–174) similar to one identified in
ELF3 [74, 75]. It is possible that cytoplasmic relocation of
ELF5 is mediated by the relative amounts of isoforms but
that this effect is not recapitulated by exogenous expres-
sion, particularly in the context of MDA-MB-231 cells,
which do not normally express ELF5 and therefore may
be lacking essential protein binding partners. Given the
importance of context in the function of ETS factors, it is
possible that the differential effects of ELF5 isoforms may
also require a stimulus (for example, growth factors) or
challenge (for example, estrogen deprivation) in order to
become apparent, an avenue that was not explored in this
study.
Conclusions
This study has characterized the expression pattern and
functions of ELF5 at the isoform level, demonstrating sig-
nificantly altered expression in cancer. Alterations in ELF5
isoform expression in cancer may drive abnormal cell fate
decisions, suggesting that ELF5, like other ETS factors,
may be a significant contributor to tumorigenesis. While
further studies are needed to clarify the mechanisms that
regulate differential ELF5 isoform expression and to fully
elucidate the role of the PNT domain, understanding ex-
pression and function at the isoform level is a vital first
step in realizing the potential of transcription factors such
as ELF5 as prognostic markers or therapeutic targets in
cancer.
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